Gossamer Bio, the San Diego-based biotech founded by former Receptos executives, has raised $276 million in its initial public offering, a total that puts it in a rare class among biotechs that have gone public in recent years.
The amount raised surpassed expectations. During the partial federal government shutdown in January, Gossamer announced it would pursue a little-used path to the public markets that required it to fix a share price, which was locked in for 20 days. But shortly thereafter the government reopened, and Gossamer announced it would reroute to the traditional path to the public markets on the terms… Read more »
UNDERWRITERS AND PARTNERS